2'-O-methyltransferase Antibody

What is 2'-O-methyltransferase and what is its primary function in RNA biology?

2'-O-methyltransferase adds a methyl group at the 2'-O position of the first nucleotide adjacent to the cap structure at the 5' end of RNA. The enzyme utilizes S-adenosylmethionine (SAM) as a methyl donor to methylate capped RNA (cap-0) resulting in a cap-1 structure. This modification plays a crucial role in distinguishing self from non-self RNA in cellular innate immunity .

In experimental settings, researchers can verify 2'-O-methylation status through in vitro methylation assays using vaccinia virus 2'-O-methyltransferase VP39, which can transfer 3H-labeled methyl groups from S-adenosyl-methionine to mRNA lacking this modification .

How does 2'-O-methylation impact RNA stability and function?

2'-O-methylation provides a protective function against RNA degradation by blocking both decapping and exoribonuclease activities. This modification specifically protects fully capped (cap1) mRNAs while allowing for selective degradation of transcripts lacking 2'-O-methylation (such as cap0 and capG) .

In research contexts, scientists can quantify the stability differences between methylated and unmethylated RNAs by monitoring RNA degradation rates following transcription inhibition with actinomycin D, using techniques such as qRT-PCR with primers spanning the 5' cap region.

How can researchers effectively study coronavirus NSP16 2'-O-methyltransferase activity in laboratory settings?

To study coronavirus NSP16 activity, researchers can employ several methodological approaches:

• In vitro methylation assays: Using purified recombinant NSP16 (and its cofactor NSP10) with RNA substrates containing a 5' cap structure. The transfer of methyl groups can be monitored using radiolabeled SAM ([3H]SAM) followed by liquid scintillation counting .

• Mutational analysis: Creating viral mutants with substitutions in the conserved K-D-K-E catalytic tetrad (particularly the D130A mutation in SARS-CoV-2), which abrogates 2'-O-methyltransferase activity. These mutants can be used to assess the role of 2'-O-methylation in viral replication and immune evasion both in vitro and in vivo .

• Immunoprecipitation: Using specific antibodies against NSP16 to isolate the enzyme and its interacting partners from infected cells. Western blotting can be performed with a 1:1000 dilution for detection .

What are the key experimental models for studying 2'-O-methyltransferase function in viral pathogenesis?

Several experimental models have proven valuable for 2'-O-methyltransferase research:

• Cell culture systems: Human fibroblast MRC-5 cells and blood-derived human macrophages have been used to study the effects of 2'-O-methyltransferase-deficient viruses on interferon production and viral replication .

• Mouse models: C57BL/6 mice, IFNAR-deficient mice, and mice lacking RNA sensors (TLR7, Mda5) have been instrumental in understanding the in vivo relevance of 2'-O-methylation in viral pathogenesis. These models have demonstrated that 2'-O-methyltransferase mutant viruses show attenuated replication and pathogenesis in wildtype mice but replicate efficiently in mice lacking key innate immune components .

• Transgenic models: Human ACE2-expressing mouse models and hamster models have been used specifically for SARS-CoV-2 research, showing differential attenuation patterns between upper and lower airways for 2'-O-methyltransferase mutants .

What are the optimal methodologies for validating antibody specificity against viral and host 2'-O-methyltransferases?

To ensure antibody specificity for 2'-O-methyltransferases, researchers should implement a multi-faceted validation approach:

• Knockout/knockdown controls: Utilizing cells with CRISPR/Cas9-mediated knockout or siRNA-mediated knockdown of the target 2'-O-methyltransferase to confirm antibody specificity.

• Recombinant protein controls: Testing antibodies against purified recombinant proteins, including wildtype and catalytically inactive mutants (e.g., mutations in the K-D-K-E motif).

• Cross-reactivity assessment: For viral studies, ensuring the antibody doesn't cross-react with host 2'-O-methyltransferases by testing in uninfected cells.

• Immunoprecipitation followed by mass spectrometry: Confirming that the immunoprecipitated protein is indeed the target 2'-O-methyltransferase.

Current antibodies like the SARS-CoV-2 2'-O-ribose Methyltransferase Antibody #70811 are optimized for western blotting (1:1000 dilution) and immunoprecipitation (1:50 dilution) applications .

How can researchers effectively distinguish between host and viral 2'-O-methyltransferase activities in infected cells?

Distinguishing between host and viral 2'-O-methyltransferase activities requires sophisticated experimental approaches:

• Substrate specificity analysis: Host enzymes (hMTr1/hMTr2) and viral enzymes have different substrate preferences and pH/salt requirements for optimal activity. For example, hMTr1 functions optimally at pH 8.4 with 150mM KCl, while some viral methyltransferases prefer different conditions .

• Subcellular fractionation: Since host methyltransferases like hMTr1 and hMTr2 have different cellular localizations (nuclear vs. throughout the cell), subcellular fractionation followed by activity assays can help distinguish between host and viral activities .

• Specific inhibitors: Utilizing selective inhibitors that target either host or viral enzymes can help differentiate their activities.

• RNA sequencing with 2'-O-methylation detection: Techniques like Nm-seq can identify the specific RNA targets and sequence contexts of different methyltransferases, which can reveal virus-specific patterns.

How does 2'-O-methylation influence innate immune responses to viral RNA?

2'-O-methylation serves as a crucial molecular signature that distinguishes self from non-self RNA:

• Pattern recognition receptor evasion: RNA lacking 2'-O-methylation is recognized by the cytoplasmic RNA sensor Mda5, leading to type I interferon production. Properly methylated viral RNAs evade this recognition .

• IFIT-mediated restriction: Interferon-induced proteins with tetratricopeptide repeats (IFITs), particularly IFIT1 and IFIT3, specifically recognize and restrict the translation of RNAs lacking 2'-O-methylation .

• Differential tissue responses: The importance of 2'-O-methylation varies between tissues, with viral 2'-O-methyltransferase mutants showing stronger attenuation in upper versus lower airways in some models .

Researchers can assess these effects by comparing wildtype and 2'-O-methyltransferase-deficient viruses in cells with knockouts of specific immune components (Mda5, IFITs) and measuring interferon production, viral replication, and gene expression profiles.

What methodologies are most effective for studying the impact of 2'-O-methylation on MDA5 and IFIT recognition in experimental settings?

To study how 2'-O-methylation affects MDA5 and IFIT recognition, researchers should consider these methodological approaches:

• RNA immunoprecipitation: Using antibodies against MDA5 or IFITs to pull down bound RNAs, followed by RNA-seq or qRT-PCR to identify and quantify bound viral RNAs with different methylation statuses.

• Reporter systems: Developing reporter mRNAs with or without 2'-O-methylation and measuring their translation efficiency in cells expressing different levels of IFITs.

• Structural biology approaches: Utilizing X-ray crystallography or cryo-EM to visualize the molecular interactions between MDA5/IFITs and differentially methylated RNAs.

• In vivo models with genetic knockouts: Comparing the replication of 2'-O-methyltransferase-deficient viruses in wildtype animals versus those lacking MDA5 or IFITs. For example, research has shown that coronavirus 2'-O-methyltransferase mutants replicate efficiently in mice lacking IFNAR or Mda5 despite being attenuated in wildtype mice .

What are the methodological considerations for developing inhibitors targeting viral 2'-O-methyltransferases?

Developing effective inhibitors of viral 2'-O-methyltransferases requires a systematic approach:

• Structure-based drug design: Utilizing crystal structures of viral 2'-O-methyltransferases (such as SARS-CoV-2 NSP16 in complex with NSP10) to identify potential binding pockets for small molecule inhibitors.

• High-throughput screening: Developing biochemical assays using purified recombinant enzymes to screen compound libraries for inhibitory activity. These assays typically measure the transfer of methyl groups from SAM to RNA substrates.

• SAM analogs: Designing competitive inhibitors based on SAM structure that can bind to the SAM-binding pocket without donating methyl groups.

• Target validation: Confirming that compounds that inhibit 2'-O-methyltransferase activity in vitro also prevent viral replication in cell culture and animal models through the intended mechanism.

• Selectivity profiling: Ensuring that inhibitors do not affect host 2'-O-methyltransferases by testing against purified human enzymes (hMTr1, hMTr2).

How can 2'-O-methyltransferase-deficient viruses be utilized in vaccine development research?

2'-O-methyltransferase-deficient viruses show promise as live attenuated vaccine candidates:

• Attenuation characterization: Thorough assessment of viral replication and pathogenesis in multiple models, including immunocompetent and immunocompromised animal models. For coronaviruses, NSP16 mutants show significant attenuation while maintaining immunogenicity .

• Genetic stability: Monitoring for reversion mutations or compensatory changes during multiple passages in cell culture and animal models.

• Protective efficacy: Evaluating the ability of 2'-O-methyltransferase-deficient viruses to induce protective immunity against challenge with wildtype virus, measuring both antibody and T cell responses.

• Safety profile: Careful assessment in models with deficiencies in innate immune components (e.g., IFNAR-deficient mice) to ensure the attenuation depends on functional host immune responses.

• Combination with other attenuating mutations: Testing whether combining 2'-O-methyltransferase deficiency with other attenuating mutations provides a more stable attenuated phenotype.

What are the optimal assays for measuring 2'-O-methyltransferase activity in different experimental contexts?

Several assays can be employed to measure 2'-O-methyltransferase activity:

• Radiometric assays: Using 3H-labeled SAM as methyl donor and measuring incorporation of radioactivity into RNA substrates by liquid scintillation counting. This approach provides quantitative results with high sensitivity .

• Thin-layer chromatography (TLC): Analyzing nuclease P1-digested, 32P-labeled RNA on 2D TLC to directly visualize and quantify methylated nucleotides (e.g., detecting pAm and pCm) .

• Mass spectrometry: LC-MS/MS analysis of nuclease-digested RNA to identify and quantify methylated nucleotides with high precision.

• Indirect measurement: Using vaccinia virus 2'-O-methyltransferase VP39 to methylate RNA isolated from cells or viruses. The level of methyl group incorporation inversely correlates with the pre-existing 2'-O-methylation status .

How can researchers accurately detect and quantify 2'-O-methylation patterns across the transcriptome?

Transcriptome-wide analysis of 2'-O-methylation requires specialized techniques:

• Nm-seq: This method specifically detects 2'-O-methylated nucleotides by exploiting their resistance to alkaline hydrolysis, providing single-nucleotide resolution across the transcriptome .

• RibOxi-seq: Oxidation-based method that leverages the protection of 2'-O-methylated nucleotides from periodate oxidation.

• CLIP-seq for methyltransferases: Cross-linking immunoprecipitation sequencing using antibodies against methyltransferases (e.g., CMTr1, CMTr2) to identify their binding sites and target RNAs .

• Polysome profiling: Comparing the translation efficiency of mRNAs with different 2'-O-methylation patterns by analyzing their distribution across polysome fractions.

• Bioinformatic analysis: Developing algorithms to identify sequence motifs and structural features associated with 2'-O-methylation sites, which can help predict methylation patterns in novel transcripts.

What experimental approaches can reveal the evolutionary significance of 2'-O-methyltransferases across viral families?

Understanding the evolutionary significance of 2'-O-methyltransferases requires comparative studies:

• Phylogenetic analysis: Constructing evolutionary trees based on 2'-O-methyltransferase sequences from diverse viral families to identify conserved domains and evolutionary relationships.

• Cross-species complementation: Testing whether 2'-O-methyltransferases from one virus can functionally complement deficiencies in another virus, providing insights into functional conservation.

• Chimeric enzyme construction: Creating fusion proteins between 2'-O-methyltransferases from different viruses to identify which domains confer substrate specificity or catalytic efficiency.

• Comparative biochemistry: Characterizing the substrate preferences, catalytic efficiencies, and cofactor requirements of 2'-O-methyltransferases from diverse viral families under standardized conditions.

• Host range analysis: Determining whether 2'-O-methyltransferase functionality correlates with viral host range by comparing activities in cells from different species.

How do human and viral 2'-O-methyltransferases differ in structure and function, and what are the implications for research methodology?

Human and viral 2'-O-methyltransferases exhibit important differences that influence research approaches:

• Structural differences: While sharing a common methyltransferase domain, viral enzymes often have unique structural features. For example, coronavirus NSP16 requires NSP10 as a cofactor, whereas human enzymes (hMTr1/hMTr2) function independently .

• Substrate specificity: Human enzymes hMTr1 and hMTr2 methylate the first and second transcribed nucleotides respectively, while viral enzymes may have different target preferences .

• Cellular localization: Human hMTr1 is nuclear, while hMTr2 is distributed throughout the nucleus and cytosol. Viral methyltransferases typically operate in specialized replication compartments .

• Research implications: These differences allow for selective targeting in antiviral development. For experimental protocols, different buffer conditions are optimal for different enzymes: hMTr1 functions best at pH 8.4 with 150mM KCl, while hMTr2 prefers pH 7.4 with 50mM KCl .

How can researchers distinguish between the functions of different 2'-O-methyltransferases when multiple enzymes are present in the same experimental system?

Differentiating between multiple 2'-O-methyltransferases requires sophisticated approaches:

• Gene-specific knockdown/knockout: Using siRNA, shRNA, or CRISPR/Cas9 to selectively deplete individual methyltransferases and assess the impact on RNA methylation patterns.

• Selective inhibitors: Developing and applying compounds that specifically inhibit individual methyltransferases based on structural differences in their active sites.

• Substrate recognition sequences: Identifying the preferred sequence contexts for different methyltransferases and using this information to create reporter RNAs that are preferentially methylated by specific enzymes.

• Catalytic mutants: Expressing catalytically inactive mutants that can compete with endogenous enzymes for substrate binding without performing methylation.

• Sequential immunoprecipitation: Using antibodies specific for different methyltransferases to sequentially deplete them from cell lysates and analyze the residual methylation activity.

What are the methodological challenges in studying the interplay between 2'-O-methylation and other RNA modifications in the context of innate immunity?

Investigating the interplay between 2'-O-methylation and other RNA modifications presents several challenges:

• Modification interdependence: Some RNA modifications may be prerequisites for others. Methodologically, this requires temporal analysis of modification deposition using pulse-chase experiments or time-course studies with inhibitors.

• Detection of multiple modifications: Developing techniques that can simultaneously detect 2'-O-methylation alongside other modifications (m6A, m1A, pseudouridine) on the same RNA molecule. Mass spectrometry-based approaches show promise for this application.

• Functional redundancy: Multiple modifications may serve similar immune evasion functions, requiring combinatorial depletion of modification enzymes to reveal phenotypes.

• Cell type-specific effects: The significance of RNA modifications for immune responses varies across cell types, necessitating comparative studies in diverse immune cell populations.

• Quantitative analysis: Developing quantitative methods to assess the stoichiometry of different modifications on the same RNA molecule, which is essential for understanding their combined impact on innate immune recognition.